U.S. Capital Wealth Advisors’s Editas Medicine EDIT Stock Holding History

U.S. Capital Wealth Advisors’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-21,593	Closed	-$192K	–	884
2022 Q4	$192K	Hold	21,593	–	–	0.01%	614
2022 Q3	$264K	Hold	21,593	–	–	0.01%	540
2022 Q2	$255K	Hold	21,593	–	–	0.01%	580
2022 Q1	$411K	Sell	21,593 -70	-0.3%	-$1.3K	0.02%	547
2021 Q4	$575K	Buy	21,663 +70	+0.3%	+$2.41K	0.02%	491
2021 Q3	$887K	Buy	+21,593	New	+$1.18M	0.04%	406

Other funds holding EDIT

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

U.S. Capital Wealth Advisors's EDIT Position: Q1 2023 in Review

U.S. Capital Wealth Advisors sold out of Editas Medicine (EDIT) in Q1 2023, closing a stake of 21,593 shares — an estimated $192K sold.

U.S. Capital Wealth Advisors first reported a position in EDIT in Q3 2021 and held it in 6 quarters. The position peaked at $887K in Q3 2021. 234 funds tracked by Wall St. Rank hold EDIT as of Q1 2023.

U.S. Capital Wealth Advisors reported no remaining Editas Medicine position as of Q1 2023 after selling out during the quarter.
U.S. Capital Wealth Advisors sold 21,593 Editas Medicine shares in Q1 2023, an estimated $192K.
U.S. Capital Wealth Advisors first reported a position in Editas Medicine in Q3 2021 and held it in 6 quarters.
U.S. Capital Wealth Advisors's Editas Medicine position peaked at $887K in Q3 2021.
234 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2023.

Based on U.S. Capital Wealth Advisors's 13F filing for Q1 2023, filed 11 May 2023.